PLIANT THERAPEUTICS I

Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023

28 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

09 Aug 2023 15:03:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis

09 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

23 Jun 2023 06:30:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

24 May 2023 07:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Events

10 May 2023 07:05:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

09 May 2023 15:02:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

30 Apr 2023 13:10:28 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference

12 Apr 2023 07:01:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference

27 Mar 2023 07:01:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis

13 Mar 2023 07:01:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results

09 Mar 2023 15:05:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors

08 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Events

01 Mar 2023 07:01:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Events

07 Feb 2023 07:01:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

02 Feb 2023 07:02:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

27 Jan 2023 15:03:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer

25 Jan 2023 07:01:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering

24 Jan 2023 20:19:04 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Proposed Public Offering of Common Stock

23 Jan 2023 15:01:00 By Nasdaq GlobeNewswire